Breaking News Instant updates and real-time market news.

CCXI

ChemoCentryx

$11.59

0.13 (1.13%)

16:23
08/09/18
08/09
16:23
08/09/18
16:23

ChemoCentryx reports Q2 EPS (14c), consensus (15c)

Reports Q2 revenue $15.02M, consensus $14.06M. "A most important milestone has recently been achieved at ChemoCentryx: we completed enrollment of over 300 patients in our landmark ADVOCATE Phase III trial in ANCA-associated vasculitis," said Thomas Schall, President and CEO of ChemoCentryx. "We're targeting the fourth quarter of 2019 for the release of top-line data from ADVOCATE, and expect that successful trial results would form the basis of our new drug application to the FDA. Our very healthy balance sheet also enables us to simultaneously pursue other high unmet need, high value disease indications. Specifically, controlled clinical trials are underway for avacopan in C3G and for our other innovative kidney asset, CCX140 in FSGS. These are all orphan renal diseases with no approved therapies. Our plan to expand into orphan dermatological disease is also progressing extremely well. We intend to launch a large controlled clinical trial of avacopan in hidradenitis suppurativa later this year. In sum, 2018 is shaping up to be a watershed year for the Company, and we believe our momentum is building."

  • 09

    Aug

CCXI ChemoCentryx
$11.59

0.13 (1.13%)

05/02/18
HCWC
05/02/18
INITIATION
Target $20
HCWC
Buy
ChemoCentryx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started ChemoCentryx with a Buy rating and $20 price target. The analyst sees "multiple value-generating earlier-stage assets within the pipeline."
05/16/18
ADAM
05/16/18
INITIATION
Target $17
ADAM
Buy
ChemoCentryx initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated ChemoCentryx with a Buy rating. The analyst views data from two Phase 2 studies evaluating avacopan as supportive of the company's ongoing Phase 3 study in ANCA-associated vasculitis, boding well for the mid-2019 readout on non-inferiority. She said the pipeline provides upside opportunity as the case study of a patient demonstrating benefit two years out is encouraging. Gilson has a $17 price target on ChemoCentryx shares.
06/28/18
RAJA
06/28/18
INITIATION
Target $18
RAJA
Strong Buy
ChemoCentryx initiated with a Strong Buy at Raymond James
Raymond James analyst Steven Seedhouse initiated ChemoCentryx with a Strong Buy and $18 price target.
07/13/18
BMOC
07/13/18
INITIATION
Target $45
BMOC
Outperform
InflaRx initiated with an Outperform at BMO Capital
As reported earlier, BMO Capital analyst Matthew Luchini initiated InflaRX (IFRX) with an Outperform rating and a price target of $45. The analyst notes that the company's IFX-1 "could be a best-in-class treatment for hidradenitis suppurativa" skin diseas, with initial data suggesting a "better clinical profile" than Humira. Luchini adds that the strength of IFX-1's Phase IIa data de-risks the ongoing Phase IIb trial, also stating that "IFX-1's targeting of C5a could be an advantage over emerging competitor avacopan" made by ChemoCentryx (CCXI).

TODAY'S FREE FLY STORIES

02:50
09/21/18
09/21
02:50
09/21/18
02:50
General news
FX Action: The dollar and yen have continued to underperform »

FX Action: The dollar and…

02:10
09/21/18
09/21
02:10
09/21/18
02:10
General news
FX Action: USD-JPY has lifted to a fresh two-month high »

FX Action: USD-JPY has…

01:45
09/21/18
09/21
01:45
09/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap: Stock…

AYI

Acuity Brands

$161.46

3.9 (2.48%)

21:35
09/20/18
09/20
21:35
09/20/18
21:35
Upgrade
Acuity Brands rating change at Wells Fargo »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

TTNP

Titan Pharmaceuticals

$0.50

-0.08 (-13.79%)

21:34
09/20/18
09/20
21:34
09/20/18
21:34
Syndicate
Titan Pharmaceuticals raises $9.5M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTEM

Molecular Templates

$5.81

-0.44 (-7.04%)

21:31
09/20/18
09/20
21:31
09/20/18
21:31
Syndicate
Molecular Templates 8.2M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

YMAB

Y-mAbs Therapeutics

$0.00

(0.00%)

21:30
09/20/18
09/20
21:30
09/20/18
21:30
Syndicate
Y-mAbs Therapeutics 6M share IPO priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VKTX

Viking Therapeutics

$18.92

-0.72 (-3.67%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Viking Therapeutics 9.5M share Secondary priced at $18.50 »

William Blair, SunTrust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TWIN

Twin Disc

$23.33

0.34 (1.48%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Twin Disc 1.333M share Secondary priced at $22.50 »

Baird and Oppenheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

FTCH

Farfetch

$0.00

(0.00%)

21:26
09/20/18
09/20
21:26
09/20/18
21:26
Syndicate
Farfetch 44.244M share IPO priced at $20.00, above the range »

Goldman Sachs, JPMorgan,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

21:25
09/20/18
09/20
21:25
09/20/18
21:25
Syndicate
Crispr Therapeutics 4.211M share Secondary priced at $47.50 »

Goldman Sachs, Piper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

MDCA

MDC Partners

$4.55

0.25 (5.81%)

21:08
09/20/18
09/20
21:08
09/20/18
21:08
Hot Stocks
MDC Partners to evaluate strategic alternatives »

MDC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$101.71

0.16 (0.16%)

20:27
09/20/18
09/20
20:27
09/20/18
20:27
Hot Stocks
Guidewire sees 5-year target revenue of about $1.3B »

Sees % subscription of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AVMXY

Avita Medical

$0.00

(0.00%)

20:13
09/20/18
09/20
20:13
09/20/18
20:13
Hot Stocks
Avita Medical announces FDA approval of RECELL in burn treatment »

AVITA Medica announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.36

-0.03 (-1.26%)

20:05
09/20/18
09/20
20:05
09/20/18
20:05
Hot Stocks
Ladenburg Thalmann CEO to serve as chairman »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.